Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $135.24 USD
Change Today +2.68 / 2.02%
Volume 3.6M
CELG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 3:31 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CELG) Snapshot

Open
$134.00
Previous Close
$132.56
Day High
$136.08
Day Low
$132.46
52 Week High
07/23/15 - $140.72
52 Week Low
10/15/14 - $83.16
Market Cap
107.2B
Average Volume 10 Days
7.3M
EPS TTM
$2.76
Shares Outstanding
793.1M
EX-Date
--
P/E TM
48.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CELG)

celgene corp (CELG) Related Businessweek News

View More BusinessWeek News

celgene corp (CELG) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CELG) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp (CELG) Key Developments

Celgene Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Celgene Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, operating income was $415.8 million against $758.9 million a year ago. Income before income taxes was $470.8 against $706.8 a year ago. Net income was $356.2 million against $597.8 million a year ago. Adjusted net income increased 36% to $1,019 million compared to $748 million for the same period last year. Operating cash flow was $284 million which included $570 million of upfront payments relating to research and development collaborations. For the six months, total revenue was $4,358.6 million against $3,602.7 million a year ago. Operating income was $1,274.8 million against $1,120.7 million a year ago. Income before income taxes was $1,297.9 against $1,039.1 a year ago. Net income was $1,075.1 million against $877.5 million a year ago. Diluted net income per common share was $1.30 against $1.05 a year ago. Net income - adjusted was $1,909.8 million against $1,452.8 million a year ago. Diluted net income per common share – adjusted was $2.30 against $1.73 a year ago. For the year 2015, GAAP diluted EPS is expected to be in the range of $2.17 to $2.46, lowered from the original range of $2.97 to $3.19. Projected net income - GAAP is expected to be between $1,798.9 million and $2, 042.5 million. Projected net income – adjusted is expected to be between $3,942.5 million and $4,025.5 million. The company announced that it is well on track to achieve net product sales guidance of $9 million to $9.5 billion and absorbing the dilutive impact of the company’s strategic deals, it actually raised adjusted EPS guidance to $4.75 to $4.85, up from earlier target of $4.60 to $4.75.

Bionor Pharma ASA Enters into Supply Agreement with Celgene Corporation

Bionor Pharma ASA has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax) for use in a planned multicenter clinical Phase II study of Bionor's most advanced and proprietary vaccine, Vacc-4x, with romidepsin. The planned study will continue to explore the ‘Kick and Kill’ strategy of Bionor's ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

Bionor Pharma ASA Signs Agreement with Celgene Corporation for Supply of Romidepsin

Bionor Pharma ASA signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax) for use in a planned multicenter clinical Phase II study of Bionor’s Vacc-4x, with romidepsin. The planned study will continue to explore the ‘Kick and Kill’ strategy of Bionor’s ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $135.24 USD +2.68

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $338.41 USD +11.43
Biogen Inc $319.04 USD +9.61
Bristol-Myers Squibb Co $64.58 USD +0.28
Medtronic PLC $77.32 USD +1.66
Valeant Pharmaceuticals International Inc C$332.56 CAD -4.93
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 50.2x
Price/Sales 12.5x
Price/Book 15.6x
Price/Cash Flow 42.9x
TEV/Sales 10.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.